Article
Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy.
BMC cancer - 23 Mar 2017
Kim Seung Tae, Lee Jeeyun, Park Se Hoon, Park Joon Oh, Park Young Suk, Kang Won Ki, Lim Ho Yeong
Abstract excerpt
BACKGROUND: We designed a single-arm, open-label phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy (#NCT02449538). METHODS: Everolimus was administered orally at a daily dose of 10 mg continuously (28-day cycles). Treatment was continued until progression of the disease or intolerable toxicity was observed. Based on...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.